{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:19:43Z","timestamp":1787642383597,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03749-3","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:43:04Z","timestamp":1787640184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physician and Patient Perception of Disease, Symptomatology, and Treatment Administration Preference in Paroxysmal Nocturnal Haemoglobinuria: Results from a Real-World Survey"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-5277","authenticated-orcid":false,"given":"Bing","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8612-7680","authenticated-orcid":false,"given":"Maria-Magdalena","family":"Balp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6634-3823","authenticated-orcid":false,"given":"Josefin","family":"Snellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5203-9797","authenticated-orcid":false,"given":"Anggie","family":"Wiyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gifty Cobby","family":"Amporful","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-6379","authenticated-orcid":false,"given":"Niall","family":"Hatchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4454-5013","authenticated-orcid":false,"given":"Yasmin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6750-2666","authenticated-orcid":false,"given":"Sarah","family":"Weatherby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scarlett","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"18","key":"3749_CR1","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804\u201311. https:\/\/doi.org\/10.1182\/blood-2014-02-522128.","journal-title":"Blood"},{"issue":"25","key":"3749_CR2","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","volume":"121","author":"A Hill","year":"2013","unstructured":"Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985\u201396. https:\/\/doi.org\/10.1182\/blood-2012-09-311381.","journal-title":"Blood"},{"issue":"Suppl 1","key":"3749_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ijlh.14281","volume":"46","author":"F Versino","year":"2024","unstructured":"Versino F, Fattizzo B. Complement inhibition in paroxysmal nocturnal hemoglobinuria: from biology to therapy. Int J Lab Hematol. 2024;46(Suppl 1):43\u201354. https:\/\/doi.org\/10.1111\/ijlh.14281.","journal-title":"Int J Lab Hematol"},{"key":"3749_CR4","unstructured":"Food and Drug Administration. Highlights of prescribing information\u2014SOLIRIS\u00ae (eculizumab) injection 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125166s448,761108s038lbl.pdf. Accessed on 16 Feb 2026"},{"issue":"7","key":"3749_CR5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00277-020-04052-z","volume":"99","author":"H Schrezenmeier","year":"2020","unstructured":"Schrezenmeier H, Roth A, Araten DJ, Kanakura Y, Larratt L, Shammo JM, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505\u201314. https:\/\/doi.org\/10.1007\/s00277-020-04052-z.","journal-title":"Ann Hematol"},{"issue":"1","key":"3749_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-024-02279-2","volume":"22","author":"EA Griffiths","year":"2024","unstructured":"Griffiths EA, Min JS, Lee WN, Yu JC, Patel Y, Myren KJ, et al. Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study. Health Qual Life Outcomes. 2024;22(1):62. https:\/\/doi.org\/10.1186\/s12955-024-02279-2.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"3749_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02016-8","volume":"16","author":"CE Schwartz","year":"2021","unstructured":"Schwartz CE, Stark RB, Borowiec K, Nolte S, Myren KJ. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria. Orphanet J Rare Dis. 2021;16(1):389. https:\/\/doi.org\/10.1186\/s13023-021-02016-8.","journal-title":"Orphanet J Rare Dis"},{"key":"3749_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2020-142327","volume":"136","author":"D Dingli","year":"2020","unstructured":"Dingli D, Matos JE, Lehrhaupt K, Krishnan S, Baver SB, Sarda SP. Work productivity loss and quality of life in paroxysmal nocturnal hemoglobinuria among patients receiving C5 inhibitors in the United States. Blood. 2020;136:3. https:\/\/doi.org\/10.1182\/blood-2020-142327.","journal-title":"Blood"},{"key":"3749_CR9","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1182\/blood-2023-182336","volume":"142","author":"D Dingli","year":"2023","unstructured":"Dingli D, Rizio AA, Broderick L, LaGasse K, Carty MK, Burton E, et al. Health-related quality of life and symptom-specific functional impairment among patients treated with parenterally administered complement inhibitors for paroxysmal nocturnal hemoglobinuria. Blood. 2023;142:5126. https:\/\/doi.org\/10.1182\/blood-2023-182336.","journal-title":"Blood"},{"issue":"5","key":"3749_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/1049732315570116","volume":"25","author":"L Garrino","year":"2015","unstructured":"Garrino L, Picco E, Finiguerra I, Rossi D, Simone P, Roccatello D. Living with and treating rare diseases: experiences of patients and professional health care providers. Qual Health Res. 2015;25(5):636\u201351. https:\/\/doi.org\/10.1177\/1049732315570116.","journal-title":"Qual Health Res"},{"issue":"2-3","key":"3749_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.healthpol.2012.02.018","volume":"105","author":"K Budych","year":"2012","unstructured":"Budych K, Helms TM, Schultz C. How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient\u2013physician interaction. Health Policy. 2012;105(2\u20133):154\u201364. https:\/\/doi.org\/10.1016\/j.healthpol.2012.02.018.","journal-title":"Health Policy"},{"key":"3749_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2019.00236","volume":"7","author":"AL Crowe","year":"2019","unstructured":"Crowe AL, McKnight AJ, McAneney H. Communication needs for individuals with rare diseases within and around the healthcare system of Northern Ireland. Front Public Health. 2019;7:236. https:\/\/doi.org\/10.3389\/fpubh.2019.00236.","journal-title":"Front Public Health"},{"issue":"8","key":"3749_CR13","doi-asserted-by":"publisher","DOI":"10.2196\/39172","volume":"24","author":"S Ashtari","year":"2022","unstructured":"Ashtari S, Taylor AD. The internet knows more than my physician: qualitative interview study of people with rare diseases and how they use online support groups. J Med Internet Res. 2022;24(8):e39172. https:\/\/doi.org\/10.2196\/39172.","journal-title":"J Med Internet Res"},{"issue":"1","key":"3749_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03207-9","volume":"19","author":"L Inhestern","year":"2024","unstructured":"Inhestern L, Otto R, Brandt M, Zybarth D, Oheim R, Schuler H, et al. Patient experiences of interprofessional collaboration and intersectoral communication in rare disease healthcare in Germany\u2014a mixed-methods study. Orphanet J Rare Dis. 2024;19(1):197. https:\/\/doi.org\/10.1186\/s13023-024-03207-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3749_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.pec.2020.09.029","volume":"104","author":"VL Merker","year":"2021","unstructured":"Merker VL, Plotkin SR, Charns MP, Meterko M, Jordan JT, Elwy AR. Effective provider-patient communication of a rare disease diagnosis: a qualitative study of people diagnosed with schwannomatosis. Patient Educ Couns. 2021;104(4):808\u201314. https:\/\/doi.org\/10.1016\/j.pec.2020.09.029.","journal-title":"Patient Educ Couns"},{"issue":"8","key":"3749_CR16","first-page":"530","volume":"14","author":"SV Pakhomov","year":"2008","unstructured":"Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care. 2008;14(8):530\u20139.","journal-title":"Am J Manag Care"},{"issue":"1","key":"3749_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01532-3","volume":"15","author":"K Weisshaar","year":"2020","unstructured":"Weisshaar K, Ewald H, Halter J, Gerull S, Schonfeld S, Senft Y, et al. Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA\/PNH). Orphanet J Rare Dis. 2020;15(1):249. https:\/\/doi.org\/10.1186\/s13023-020-01532-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"3749_CR18","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372. https:\/\/doi.org\/10.1185\/03007990802457040.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"3749_CR19","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, Doslikova K, Davis VA, Karavali M, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39(12):1707\u201315. https:\/\/doi.org\/10.1080\/03007995.2023.2279679.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"3749_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352. https:\/\/doi.org\/10.1136\/bmjopen-2015-010352.","journal-title":"BMJ Open"},{"key":"3749_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/dmso.s120101","volume":"9","author":"V Higgins","year":"2000","unstructured":"Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2000;9:371\u201380. https:\/\/doi.org\/10.2147\/dmso.s120101.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"6846","key":"3749_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","volume":"305","author":"JE Brazier","year":"1992","unstructured":"Brazier JE, Harper R, Jones NM, O\u2019Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160\u20134. https:\/\/doi.org\/10.1136\/bmj.305.6846.160.","journal-title":"BMJ"},{"issue":"3","key":"3749_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"Group TE","year":"1990","unstructured":"Group TE. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9.","journal-title":"Health Policy"},{"key":"3749_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jhealeco.2017.06.013","volume":"55","author":"M Hernandez-Alava","year":"2017","unstructured":"Hernandez-Alava M, Pudney S. Econometric modelling of multiple self-reports of health states: the switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis. J Health Econ. 2017;55:139\u201352. https:\/\/doi.org\/10.1016\/j.jhealeco.2017.06.013.","journal-title":"J Health Econ"},{"issue":"5","key":"3749_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jval.2019.10.017","volume":"23","author":"M Hernandez Alava","year":"2020","unstructured":"Hernandez Alava M, Pudney S, Wailoo A. The EQ-5D-5L value set for England: findings of a quality assurance program. Value Health. 2020;23(5):642\u20138. https:\/\/doi.org\/10.1016\/j.jval.2019.10.017.","journal-title":"Value Health"},{"issue":"2","key":"3749_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63\u201374. https:\/\/doi.org\/10.1016\/s0885-3924(96)00274-6.","journal-title":"J Pain Symptom Manag"},{"issue":"11","key":"3749_CR27","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","volume":"21","author":"I Montan","year":"2018","unstructured":"Montan I, Lowe B, Cella D, Mehnert A, Hinz A. General population norms for the functional assessment of chronic illness therapy (FACIT)-fatigue scale. Value Health. 2018;21(11):1313\u201321. https:\/\/doi.org\/10.1016\/j.jval.2018.03.013.","journal-title":"Value Health"},{"issue":"1","key":"3749_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-023-00609-4","volume":"7","author":"D Cella","year":"2023","unstructured":"Cella D, Johansson P, Ueda Y, Tomazos I, Gustovic P, Wang A, et al. Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data. J Patient Rep Outcomes. 2023;7(1):63. https:\/\/doi.org\/10.1186\/s41687-023-00609-4.","journal-title":"J Patient Rep Outcomes"},{"issue":"5","key":"3749_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"3749_CR30","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0178","volume":"12","author":"P Wojciechowski","year":"2023","unstructured":"Wojciechowski P, Wdowiak M, Hakimi Z, Wilson K, Fishman J, Nazir J, et al. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France. J Comp Eff Res. 2023;12(5):e220178. https:\/\/doi.org\/10.57264\/cer-2022-0178.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"3749_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03178-x","volume":"19","author":"H Yu","year":"2024","unstructured":"Yu H, Duan S, Wang P, Fu R, Lv Z, Yu Y, et al. Health-related quality of life and influencing factors of patients with paroxysmal nocturnal hemoglobinuria in China. Orphanet J Rare Dis. 2024;19(1):186. https:\/\/doi.org\/10.1186\/s13023-024-03178-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3749_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12185-023-03698-5","volume":"119","author":"N Obara","year":"2024","unstructured":"Obara N, Usuki K, Hayashi T, Fujii M, Ikezoe T. Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors. Int J Hematol. 2024;119(3):255\u201364. https:\/\/doi.org\/10.1007\/s12185-023-03698-5.","journal-title":"Int J Hematol"},{"issue":"1","key":"3749_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40359-022-00786-9","volume":"10","author":"A Trognon","year":"2022","unstructured":"Trognon A, Tinti E, Beaupain B, Donadieu J, Musiol M. Establishment of MOS-SF36 percentile ranks in the general youth French population. BMC Psychol. 2022;10(1):74. https:\/\/doi.org\/10.1186\/s40359-022-00786-9.","journal-title":"BMC Psychol"},{"issue":"7","key":"3749_CR34","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s11136-019-02161-5","volume":"28","author":"K Roser","year":"2019","unstructured":"Roser K, Mader L, Baenziger J, Sommer G, Kuehni CE, Michel G. Health-related quality of life in Switzerland: normative data for the SF-36v2 questionnaire. Qual Life Res. 2019;28(7):1963\u201377. https:\/\/doi.org\/10.1007\/s11136-019-02161-5.","journal-title":"Qual Life Res"},{"issue":"2","key":"3749_CR35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00277-021-04715-5","volume":"101","author":"D Dingli","year":"2022","unstructured":"Dingli D, Matos JE, Lehrhaupt K, Krishnan S, Yeh M, Fishman J, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251\u201363. https:\/\/doi.org\/10.1007\/s00277-021-04715-5.","journal-title":"Ann Hematol"},{"key":"3749_CR36","unstructured":"National Institute for Health and Care Excellence. Iptacopan for treating paroxysmal nocturnal haemoglobinuria 2024. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1000\/resources\/iptacopan-for-treating-paroxysmal-nocturnal-haemoglobinuria-pdf-2973528206577349. Accessed on 17 Feb 2025"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03749-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:43:05Z","timestamp":1787640185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03749-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":36,"alternative-id":["3749"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03749-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bing Han declares that he has no competing interests. Talha Munir has received honorarium from BeiGene, Sobi, and Gilead; honorarium, member of advisory committee for Astra Zeneca, Alexion, Novartis, Roche; honorarium, member of advisory committee, research support from Janssen and AbbVie. Maria-Magdalena Balp and Josefin Snellman are employees of Novartis Pharma AG, Basel, Switzerland. Anggie Wiyani is employee of Novartis Pharmaceuticals UK Ltd, London, UK. Gifty Cobby Amporful is an employee of Novartis Pharmaceuticals Corporation, East Hanover, United States of America. Yasmin Taylor, Sarah Weatherby, Niall Hatchell were employees of ARW at time of study. Scarlett Che and Jordi Cruz reports honoraria and consultancy for Novartis.","order":1,"name":"Ethics","label":"Conflict of Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients consented to inclusion in the DSP using a check box on the survey and all data were aggregated and de-identified before receipt. Exemption from ethical review for the Adelphi Real World PNH DSP was sought and obtained from Pearl Institutional Review Board (Protocol number 21-ADRW-127). All surveys were done in full accordance with relevant legislation and guidance at the time of data collection, including the European Pharmaceutical Marketing Research Association (EphMRA) guidelines, and followed the principles of the Helsinki Declaration of 1964 and subsequent amendments.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}